Answers are grounded in this paper and cite their sources.
INTRODUCTION: This study was designed to investigate the relationship between serum adiponectin and testosterone in patients with type 2 diabetes. MATERIALS AND METHODS: Serum level of adiponectin and testosterone were prospectively measured in 65 patients with type 2 diabetes and in 20 healthy subjects. Testosterone was determined by the radio-immunoassay whereas adiponectin levels were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: The average serum testosterone did not differ between the diabetes and the control group, but the average adiponectin in the diabetes group was lower (14.6 (14.2-15.0) vs. 24.3 (24.05-24.55) ng/mL, P = 0.001). In the diabetes group, the serum adiponectin level in patients with renal dysfunction (22.3 (21.5-23.1) ng/mL) was higher than in patients with no complications (12.1 (11.45-12.75) ng/mL) and than in patients with coronary artery disease (11.2 (10.25-12.15) ng/mL) (P = 0.009). Univariate correlation analysis showed an inverse weak correlation between adiponectin and testosterone concentrations in male diabetic patients (r = -0.27, P = 0.009). There was no significant correlation between adiponectin and testosterone in female patients (r = -0.05, P = 0.167). CONCLUSIONS: We conclude that patients with type 2 diabetes have lower serum adiponectin concentration than healthy individuals, and that there is a weak inverse correlation between adiponectin and testosterone serum concentrations in male diabetics.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: